# Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer

> **NCT03798639** · PHASE1 · COMPLETED · sponsor: **Claire Verschraegen** · enrollment: 7 (actual)

## Conditions studied

- Merkel Cell Carcinoma
- Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8
- Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8

## Interventions

- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Nivolumab
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03798639
- **Lead sponsor:** Claire Verschraegen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-07
- **Primary completion:** 2022-12-02
- **Final completion:** 2022-12-02
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03798639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03798639, "Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT03798639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*